Orcosa

Orcosa is a private, pre-revenue biotech developing a next-generation drug delivery platform called RITe™. The technology enables tablets that disintegrate in under three seconds in the buccal cavity, aiming to improve drug absorption, speed of onset, and patient compliance, particularly for those with swallowing difficulties. The company's most advanced candidate, ORC-144, is in Phase 1/2 trials for acute postoperative pain, positioning Orcosa in the large and growing market for non-opioid pain therapeutics and novel drug delivery systems. Leadership has bolstered the team with key appointments like a Chief Medical Officer, and the company maintains its own cGMP manufacturing facility in New Jersey.

Rapid Infusion Technology (RITe™) Platform: A proprietary orally disintegrating and buccal tablet technology designed to disintegrate in <3 seconds, adhere to the buccal mucosa, and enable rapid drug absorption with potential for enhanced bioavailability and faster onset of action.

Orcosa competes in the advanced drug delivery space against large-cap companies with ODT technologies (e.g., Catalent, Adare Pharma Solutions) and innovators in buccal/sublingual delivery. In the pain segment, it competes with numerous biotechs developing novel analgesics, including other cannabinoid-based therapies with different delivery mechanisms.